The treatment of depressive states with G 22355 (imipramine hydrochloride).
about
Efficacy of antidepressants in adultsX-ray structure of dopamine transporter elucidates antidepressant mechanismEarly onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysisEpigenetic effect of chronic stress on dopamine signaling and depressionSerotonin-kynurenine hypothesis of depression: historical overview and recent developmentsThe International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of GuidelinesTriple uptake inhibitors: therapeutic potential in depression and beyondWere we all asleep at the switch? A personal reminiscence of psychiatry from 1940 to 2010The GABAβ receptor as a target for antidepressant drug actionThe fallacy of the medical model and the dangers of psychotropic drugs as a mode of treatment for mental disorders.The genetics of major depression: moving beyond the monoamine hypothesis.Binding and orientation of tricyclic antidepressants within the central substrate site of the human serotonin transporter.Chronic treatment with lithium or desipramine alters discharge frequency and norepinephrine responsiveness of cerebellar Purkinje cells.Recent advances in antidepressant drug treatment.Modelling cognitive affective biases in major depressive disorder using rodents.Stuck in a rut: rethinking depression and its treatment.Antidepressants versus placebo in major depression: an overviewThe effect of iproniazid and imipramine on the blood platelet 5-hydroxytrptamine level in manRecent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters.Amine neurochemistry and aggression in crayfish.Child psychiatry: an observation.Advances in the Management of Treatment-Resistant DepressionAntidepressants in the general hospital.Use of imipramine (tofranil) in the aged chronically illImipramine (tofranil) in mental health clinic and private practice.Clinical Evaluation of a New Antidepressant Agent: Tranylcypromine with Trifluoperazine (Parstelin)New pharmacological approaches to the management of depression: from theory to clinical practice.Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder.Roland Kuhn-100th Birthday of an Innovator of Clinical PsychopharmacologyHypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome.Phosphorylation of MeCP2 at Ser421 contributes to chronic antidepressant action.A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis.The problem of tricyclic antidepressant poisoning.The neural plasticity theory of depression: assessing the roles of adult neurogenesis and PSA-NCAM within the hippocampus.Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UKChemobehavioural phenomics and behaviour-based psychiatric drug discovery in the zebrafishModulation of neuronal serotonin uptake by a putative endogenous ligand of imipramine recognition sites.Trussed in evidence? Ambiguities at the interface between clinical evidence and clinical practice.Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?
P2860
Q24555325-9DD56173-80E5-486E-85F5-E7386E3FADD8Q24612997-C222E831-D2DC-46C8-BBAC-A6F976938AC9Q24647799-54179D0E-00AA-4AF1-91C2-9D2FBBAB9666Q26828593-97374EE2-AB6A-4753-BE99-083F2806FE90Q27012779-95D03C6C-3BC7-4117-AA2B-D752C0156F3CQ28076486-8E767841-A3CD-49B2-9EA5-AC9E231867B5Q28241732-EFCE986A-3E30-4174-96A3-B562B235F70BQ28287496-76ADAA93-B47D-42E2-A087-3F23DBB96755Q28476654-BCDBD055-8C34-4511-9CF9-537B019AB781Q30355790-4207EBB9-AB5B-4D39-B257-2C598D6A826FQ33669125-B2DEE1D1-11E9-488B-A80B-4FEE3958F6D2Q33707171-7C59E346-4465-46A1-8233-FFC4D04CE297Q33983640-8C8F08F4-E374-434B-9D2B-BEA82C005E62Q34107431-7D3C1B78-F4A1-4DB5-88BC-2C212A603B8AQ34349717-77F23C40-AC5D-4B48-A36F-66ADD0DA043FQ34459160-E998E034-B8EB-4D67-99A7-D5EA0CF99F5CQ34495779-A13F4764-3F64-4559-A000-B43A67CADF51Q34692193-8655EB90-C2BF-4927-A6D2-5F5D77DFECADQ34989213-CEDBF098-A798-4362-AFC0-5BBEC146EB79Q35050013-91FF911A-077E-4E7E-A99B-85219EB96E79Q35368411-187AC492-0F07-4342-AB21-088F281287E3Q35580600-A0E4A451-389F-4CBF-98B5-4A36D4DA8F75Q35674766-7BEE680E-17DF-4D02-8E6A-978A51E5FDFCQ35921998-90CCE4BF-0749-4613-A59F-862FD26C33ACQ35922787-F5672A6D-4BF3-42ED-B8CA-53390348FE8FQ35923642-1E02B8CD-BE4D-4673-80C6-1333668CE46CQ36088772-6EB73057-4A6D-404B-A88F-4CCAEDDEF98EQ36132042-3388C622-32EF-403F-A423-2D0BFE7F67BEQ36163294-8434C087-A16C-4A57-B840-2E5806B3F03AQ36215413-1F75C83A-006F-4399-92C8-5E3621B1A6C0Q36345216-54B1EB12-352F-4585-8029-1CF5C74F0798Q36546223-E02B5773-55C8-489C-8EEB-8C4CAB564E46Q36721010-A943F9E6-F908-4881-AF52-BC63E8C99DE2Q36830911-11792497-A361-44BF-B159-291E44FE7D29Q36842508-71858FA4-07E5-46A4-BD7E-A3B8C6A17849Q37265890-99FA2E78-2AED-4A25-B6E9-C41EA4110807Q37346649-4192E3BC-8074-4DFB-B162-A2BEF5E1DF05Q37416878-D1CC2262-F750-465F-A933-BF04470B5FF0Q37891098-6FA9F9FF-CC31-4212-ABC4-4937E07BE38CQ37958033-91EBE280-27E9-4D3E-89B7-508042CEBE0E
P2860
The treatment of depressive states with G 22355 (imipramine hydrochloride).
description
1958 nî lūn-bûn
@nan
1958 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1958 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1958年の論文
@ja
1958年論文
@yue
1958年論文
@zh-hant
1958年論文
@zh-hk
1958年論文
@zh-mo
1958年論文
@zh-tw
1958年论文
@wuu
name
The treatment of depressive states with G 22355 (imipramine hydrochloride).
@ast
The treatment of depressive states with G 22355 (imipramine hydrochloride).
@en
The treatment of depressive states with G 22355
@nl
type
label
The treatment of depressive states with G 22355 (imipramine hydrochloride).
@ast
The treatment of depressive states with G 22355 (imipramine hydrochloride).
@en
The treatment of depressive states with G 22355
@nl
prefLabel
The treatment of depressive states with G 22355 (imipramine hydrochloride).
@ast
The treatment of depressive states with G 22355 (imipramine hydrochloride).
@en
The treatment of depressive states with G 22355
@nl
P356
P1476
The treatment of depressive states with G 22355 (imipramine hydrochloride).
@en
P2093
P304
P356
10.1176/AJP.115.5.459
P407
P577
1958-11-01T00:00:00Z